Hamburg vows FDA/USP teamwork to fight drug adulteration

Updating public standards to meet new threats brought on by globalization is a top area for FDA and USP collaboration, says FDA commissioner Margaret Hamburg. The distribution of adulterated heparin that proved lethal several years ago is but one reason why. Hamburg describes three collaboration initiatives: joint assessment of physical reference standards, information exchanges on hand-held device applications that screen drugs for adulteration or contamination, and FDA assistance to USP in modernizing monographs to better assess and characterize drug ingredients and products. Release

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.